BAYZF (Bayer AG) Beneish M-Score: -2.78 (As of Jun. 25, 2026)


BAYZF Bayer AG BAYZF
53 GF Score
Price $53.20
GF Value $31.90
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Bayer AG Beneish M-Score?

Bayer AG BAYZF +20.72% 53 Beneish M-Score is -2.78 as of Jun. 25, 2026. GuruFocus rates BAYZF with a GF Score™ of 53/100 and a GF Value™ of $31.90 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 911 Drug Manufacturers companies, Bayer AG ranks better than 73.22% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.78 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Bayer AG's Beneish M-Score or its related term are showing as below:

BAYZF' s Beneish M-Score Range Over the Past 10 Years
Min: -3.43   Med: -2.79   Max: -1.94
Current: -2.78

During the past 13 years, the highest Beneish M-Score of Bayer AG was -1.94. The lowest was -3.43. And the median was -2.79.


Bayer AG Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Bayer AG's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bayer AG Beneish M-Score Chart

Bayer AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.41 -2.61 -2.93 -2.87 -2.84

Bayer AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.00 -3.00 -2.82 -2.84 -2.78

BAYZF vs LLY, JNJ, ABBV: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, Bayer AG's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bayer AG Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Bayer AG's Beneish M-Score falls into.


BAYZF
53GF Score
Bayer AG BAYZF
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bayer AG Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Bayer AG for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0124+0.528 * 0.9101+0.404 * 0.9894+0.892 * 1.0483+0.115 * 2.1915
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9574+4.679 * -0.06899-0.327 * 1.2105
=-2.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was $17,423 Mil.
Revenue was 15497.11 + 13393.443 + 11338.028 + 12386.39 = $52,615 Mil.
Gross Profit was 9448.555 + 8122.951 + 6282.864 + 7352.941 = $31,207 Mil.
Total Current Assets was $40,810 Mil.
Total Assets was $124,791 Mil.
Property, Plant and Equipment(Net PPE) was $14,713 Mil.
Depreciation, Depletion and Amortization(DDA) was $3,334 Mil.
Selling, General, & Admin. Expense(SGA) was $17,103 Mil.
Total Current Liabilities was $38,682 Mil.
Long-Term Debt & Capital Lease Obligation was $0 Mil.
Net Income was 3194.22 + -4399.297 + -1130.282 + -229.527 = $-2,565 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = $0 Mil.
Cash Flow from Operations was -2073.988 + 4920.375 + 1977.7 + 1220.3 = $6,044 Mil.
Total Receivables was $16,417 Mil.
Revenue was 14851.892 + 12281.675 + 11063.263 + 11995.694 = $50,193 Mil.
Gross Profit was 8770.811 + 6289.005 + 5413.984 + 6620.022 = $27,094 Mil.
Total Current Assets was $37,656 Mil.
Total Assets was $118,036 Mil.
Property, Plant and Equipment(Net PPE) was $14,160 Mil.
Depreciation, Depletion and Amortization(DDA) was $9,633 Mil.
Selling, General, & Admin. Expense(SGA) was $17,041 Mil.
Total Current Liabilities was $30,226 Mil.
Long-Term Debt & Capital Lease Obligation was $0 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(17423.121 / 52614.971) / (16417.297 / 50192.524)
=0.331144 / 0.327086
=1.0124

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(27093.822 / 50192.524) / (31207.311 / 52614.971)
=0.539798 / 0.593126
=0.9101

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (40810.405 + 14713.295) / 124790.751) / (1 - (37656.216 + 14160) / 118035.676)
=0.555066 / 0.561012
=0.9894

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=52614.971 / 50192.524
=1.0483

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(9632.859 / (9632.859 + 14160)) / (3334.114 / (3334.114 + 14713.295))
=0.404863 / 0.184742
=2.1915

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(17102.854 / 52614.971) / (17040.656 / 50192.524)
=0.325057 / 0.339506
=0.9574

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((0 + 38682.081) / 124790.751) / ((0 + 30225.946) / 118035.676)
=0.309976 / 0.256075
=1.2105

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-2564.886 - 0 - 6044.387) / 124790.751
=-0.06899

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Bayer AG has a M-score of -2.72 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.78 mean?
Bayer AG (BAYZF) has a Beneish M-Score of -2.78 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bayer AG and its competitors. According to the industry distribution chart, Bayer AG ranks #244 out of 911 companies in the Drug Manufacturers industry, placing it in the top 26.8%.
Is Bayer AG's Beneish M-Score too high?
Bayer AG's current Beneish M-Score is -2.78. Based on the distribution chart, Bayer AG ranks #244 out of 911 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bayer AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bayer AG's Beneish M-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Bayer AG ranks #244 out of 911 companies for Beneish M-Score. This puts Bayer AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bayer AG and its competitors. Bayer AG's current Beneish M-Score is -2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bayer AG stock overvalued right now?
Based on GuruFocus' analysis, Bayer AG (BAYZF) is currently considered Significantly Overvalued. The stock's GF Value™ is $31.90, compared to a current price of $53.20 — trading 66.8% above its estimated fair value. The current Beneish M-Score is -2.78. Bayer AG's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Bayer AG (BAYZF), the current Beneish M-Score is -2.78 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bayer AG (BAYZF) Overvalued in 2026?

Based on GuruFocus' analysis, Bayer AG stock appears to be overvalued. The current stock price of $53.20 is trading 66.8% above its estimated GF Value™ of $31.90. GuruFocus considers Bayer AG to be Significantly Overvalued.

Key valuation signals for BAYZF:

  • Beneish M-Score: -2.78
  • GF Value™: $31.90 vs. price of $53.20 (66.8% above fair value)
  • GF Score™: 53/100 with 2 warning signs

No single metric tells the full story. See the BAYZF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bayer AG Business Description

Address Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368
Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs (about 38% of total sales in 2025) as well as vitamins and other consumer healthcare products (13% of total). The firm's crop science business (47% of total) sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.
53GF Score

Get the complete analysis for BAYZF

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$53.20
Price
$31.90
GF Value